Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Non-small-cell lung cancer (NSCLC) is associated with a high incidence of brain metastasis (BM), and the prognosis of patients with NSCLC and BM is poor. This study aimed to identify the prognostic factors and elucidate the survival rates of Japanese patients with NSCLC and BM at initial diagnosis.

Methods: HOT 1701 is a retrospective multicenter study of patients with NSCLC and BM at initial diagnosis. The medical records of all consecutive patients diagnosed with advanced or recurrent NSCLC and BM at 14 institutions of the Hokkaido Lung Cancer Clinical Study Group Trial (HOT) in Japan were reviewed. The participants were categorized based on the presence or absence of driver mutations. The Kaplan-Meier method was used to estimate median overall survival (OS). Univariate and multivariate analyses were performed to identify prognostic factors in these patients.

Results: Among 566 patients with NSCLC and BM, the median OS was 11.8 months. Patients with driver mutations survived longer than those without driver mutations. The univariate and multivariate analyses revealed 6 independent prognostic factors: age ≥65 years, poor performance status, T factor, absence of driver gene mutations, presence of extracranial metastases, and number of BM. According to the prognostic score based on these 6 factors, the patients were stratified into 3 risk groups: low-, intermediate-, and high-risk, with median OS of 27.8, 12.2, and 2.8 months, respectively.

Conclusions: We developed a new prognostic model for patients with NSCLC and BM, which may help determine prognosis at diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558066PMC
http://dx.doi.org/10.1093/noajnl/vdae168DOI Listing

Publication Analysis

Top Keywords

patients nsclc
20
prognostic factors
16
lung cancer
12
driver mutations
12
retrospective multicenter
8
multicenter study
8
hot 1701
8
patients
8
identify prognostic
8
nsclc initial
8

Similar Publications

Single-Cell RNA Sequencing Reveals Potential Mechanism of RUNX3 Reshaping Tumor Microenvironment in Non-small-cell Lung Cancer.

Ann Surg Oncol

September 2025

Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China.

Background: RUNX3 acts as a tumor suppressor gene in non-small-cell lung cancer (NSCLC), yet its specific biological mechanism is still unclear. This study aimed to uncover tumor microenvironment (TME) changes in NSCLC with varying RUNX3 expression statuses through single-cell RNA sequencing.

Patients And Methods: In total, seven patients with NSCLC with detailed pathological data were involved, with three both paracancerous and cancerous tissue samples.

View Article and Find Full Text PDF

KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.

Crit Rev Oncol Hematol

September 2025

Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier

Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.

View Article and Find Full Text PDF

Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.

ESMO Open

September 2025

Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy.

Background: Immunotherapy has rapidly changed the treatment of early-stage non-small-cell lung cancer (NSCLC) in recent years. We aimed to summarize available evidence on the use of immunotherapy in neoadjuvant/perioperative and adjuvant settings for resectable NSCLC and explore some controversial subgroups.

Materials And Methods: Systematic literature research was carried out for randomized controlled trials of neoadjuvant/perioperative chemo-immunotherapy or adjuvant immunotherapy for resectable NSCLC.

View Article and Find Full Text PDF